Investing
Bitcoin could reach a cycle high of as much as $150,000 in 2025, driven by the so-called halving event and institutional inflow brought by...
Hi, what are you looking for?
Repay Down
Investing
Cisco Systems Inc. gave some more details on the timing of revenue from its anticipated orders related to artificial intelligence, and it looks like...
Investing
Long-term investors have been well served by index funds, which often charge very low fees and can be hard for active portfolio managers to...
Investing
If you see a headline that a company beat analysts’ expectations when reporting its quarterly results, it may not mean very much. The analysts...
Investing
A biopic based on the life of tech billionaire Elon Musk is in development at film studio A24, according to a new report from...
Investing
Oil futures climbed Thursday, shaking off data that pointed to weak Chinese consumer demand to finish higher after a two-day drop that left crude...
Investing
By Stephen Nakrosis Plug Power said unprecedented supply challenges to the North American hydrogen network have hurt financial performance this year, but that it...
Investing
Hedging equity exposure with bond investments did not work out as hoped last year. The S&P 500 fell by 19.4% and instead of moving...
Investing
By Stephen Nakrosis The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria. Valneva...
Investing
By Stephen Nakrosis Blank-check company Arago Acquisition withdrew its planned initial public offering in a filing with the Securities and Exchange Commission. In its...
Investing
By Stephen Nakrosis Biolingus (Cayman) on Thursday said it had downsized its planned initial public offering to 360,000 shares and boosted its expected share...
Investing
Week in Review Asian equities were mixed this week, which began with gains in Korea on a short sale ban. Growth stocks and sectors...
Investing
By Ben Glickman Neurocrine Biosciences and Lupin resolved patent litigation related to Neurocrine’s Ingrezza medication. Lupin will have the right to sell generic versions...
